RADNOR, Pa., April 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against Maravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQ: MRVI) on behalf of those who purchased or otherwise acquired Maravai securities between August 7, 2024, and February 24, 2025, inclusive (the “Class Period”). The lead plaintiff deadlin ...

RADNOR, Pa., April 10, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. ("Maravai") (NASDAQ: MRVI) on behalf of those who purchased or otherwise acquired Maravai securities between August 7, 2024, and February 24, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is May 5, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Mara ...

NEW YORK, April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=140985&fro ...

Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making false and misleading statements regarding its financial reporting and business operations during the specified Class Period from August 7, 2024, to February 24, 2025 [1]. Group 1: Allegations Against Maravai - The complaint alleges that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [3]. - It is claimed that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [3]. - The lawsuit also states that Maravai's goodwill was overstated, leading to materially misleading positive statements about the company's business and prospects [3]. Group 2: Legal Process for Investors - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [4]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the proposed class [4]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Maravai LifeSciences Holdings, Inc. due to allegations of violations of federal securities laws related to financial reporting and revenue recognition [2][4]. Group 1: Allegations and Financial Reporting Issues - The complaint alleges that Maravai lacked adequate internal controls over financial reporting, leading to inaccurate revenue recognition during fiscal 2024 [4]. - An identified error resulted in approximately $3.9 million in revenue being incorrectly recorded, affecting the company's financial statements [5]. - The company also indicated a material weakness in its internal controls over revenue recognition and is assessing a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC [5]. Group 2: Market Reaction - Following the announcement of the financial reporting issues, Maravai's share price fell by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, with unusually heavy trading volume [6]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $50,000 between August 7, 2024, and February 24, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - There is a deadline of May 5, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against Maravai [2][7].

Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial reporting during the Class Period from August 7, 2024, to February 24, 2025 [1][2]. Group 1: Allegations Against Maravai - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2]. - It is alleged that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [2]. - The complaint states that Maravai's goodwill was overstated, leading to misleading positive statements about the company's business and prospects [2]. Group 2: Lead Plaintiff Process - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [3]. - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages affected investors to contact them for more information [4]. - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

NEW YORK, April 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Maravai LifeSciences To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, ...

THE LEAD PLAINTIFF PROCESS: Maravai investors may, no later than May 5, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also a ...

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United ...